{name}
{subtitle}
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~14 mi. (Lausanne, Switzerland, +199 more cities)
facility
CHUV (centre hospitalier universitaire vaudois) ( Site 0712)
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
city
~14 mi. (Lausanne, Switzerland, +34 more cities)
facility
CHUV (centre hospitalier universitaire vaudois) ( Site 0333)
drug
lenvatinib, +2 more drugs
drug type
immunotherapy, +1 more type
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
city
~14 mi. (Lausanne, Switzerland, +21 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 4602)
drug
lenvatinib, +2 more drugs
drug type
immunotherapy, +1 more type
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
city
~14 mi. (Lausanne, Switzerland, +27 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 2602)
drug
lenvatinib, +3 more drugs
drug type
immunotherapy, +1 more type
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
city
~14 mi. (Lausanne, Switzerland, +30 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)
drug
lenvatinib, +4 more drugs
drug type
immunotherapy, +2 more types
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
city
~14 mi. (Lausanne, Switzerland, +24 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602)
drug
MK-4830, +3 more drugs
CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)
city
~14 mi. (Lausanne, Switzerland)
facility
CHUV Oncology Department
biomarker
ER Negative, +2 more biomarkers
drug
CMP-001, +1 more drug
drug type
immunotherapy, +2 more types
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~57 mi. (Genève, Switzerland, +145 more cities)
facility
Hopitaux Universitaires de Geneve HUG ( Site 1706)
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~57 mi. (Genève, Switzerland, +105 more cities)
facility
Hopitaux Universitaires de Geneve HUG. ( Site 1406)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions